Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2021-09-06 | Ziccum | Ziccum AB: BioStock: Ziccum siktar mot licensavtal | Pressreleaser | Visa Stäng |
|
||||
2021-06-11 | Ziccum | Ziccum AB: BioStock: Ziccums vd om kommande milstolpar | Pressreleaser | Visa Stäng |
|
||||
2021-03-31 | Ziccum | Ziccum AB: BioStock: Ziccum tar en aktiv roll i debatten om vaccintillgången | Pressreleaser | Visa Stäng |
|
||||
2021-02-18 | Ziccum | Ziccum AB: BioStock: Ziccum om samarbetet med Janssen | Pressreleaser | Visa Stäng |
|
||||
2020-11-11 | Ziccum | Ziccum AB carries out list change to Nasdaq First North Growth Market and releases company description | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-11-11 | Ziccum | Ziccum AB genomför listbyte till Nasdaq First North Growth Market och offentliggör bolagsbeskrivning | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-11-09 | Ziccum | Ziccum AB: Penser Access: Ziccum - Ett intensivt 2020, präglat av pandemin ur flera perspektiv | Pressreleaser | Visa Stäng |
|
||||
2020-11-06 | Ziccum | Ziccum AB: ZICCUM AB Delårsrapport 1 januari-30 september 2020 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2020-11-06 | Ziccum | Ziccum AB: ZICCUM AB interim report January 1-September 30, 2020 | Rapporter | Ladda ner | Visa Stäng |
Rapporter |
Ziccum AB: ZICCUM AB interim report January 1-September 30, 2020
Jul-Sep 2020 Net sales SEK 0 KSEK (0) Operating profit -5,317 KSEK (-1,380) Earnings per share before and after dilution -0.56 SEK (-0.23) Jan-Sep 2020 Net sales 0 KSEK (0) Operating profit -14,006 KSEK (-5,378) Earnings per share before and after dilution -1.75 SEK (-0.90) Significant events during the third quarter (Jul-Sep) 2020
Significant events during the reporting period (Jan-Sep) 2020
Significant events after the reporting period
Summary financial highlights 2020 2019 2020 2019 2019 CEO Statement Vaccinations are and have long been one of the best ways to prevent pandemics and epidemics. The need has never been greater than today. New travel habits, population growth, climate change and overcrowding are all potential risk factors for epidemics and pandemics. It is children who are most vulnerable; one child in five still does not receive adequate vaccination protection. Approximately 1.5 million children die each year from diseases for which vaccines are available. Ziccum has a world-unique and patented technology – LaminarPace[TM] – which enables us to produce vaccines in dry powder form, which is not practically or economically possible with conventional technologies. The benefits are many. It increases the stability and thus the lifespan of the vaccine, it facilitates the entire transport chain from factory to patient and it enables the distribution of vaccines to new places where, for example, cold and freezer storage is a major challenge – enabling more vaccination at a lower cost. Ziccum’s focus is in three main areas. Development of thermostable formulations of vaccines, preparations for production on a commercial scale and external collaborations with industrial actors who develop vaccines and also, very importantly for the industry, NGOs – non-governmental organizations. Despite Covid-19, our internal work continues on developing thermostable formulations of vaccines. In collaboration with our academic partner, the world-leading university of viruses and vaccines in Marseille, several interesting and important projects are now underway. The results are very promising, and strongly consistent with what we have seen before, we will also strengthen our patent portfolio further using these results. A strong IP portfolio is the basis for being able to enter into commercial collaborations and create value for our shareholders. Another cornerstone for making our technology commercially attractive is to prepare for production on a commercial scale. In collaboration with Swedish KeyPlants AB, we have developed a so-called Conceptual Design of a facility for filling and packaging dry vaccines based on our technology. We see large cost savings in production when compared to freeze-drying, which is a very common, but expensive, way of stabilizing vaccines. On the one hand, large capital costs are saved, but above all the need for energy is reduced by about 80%, which is in line with the UN’s seventh development goal: Sustainable energy for all. The plant can produce up to 300 million doses per year. Vaccines are a low-cost product in large parts of the world, which is why these results are so important. Now that we can describe a production facility, we have expanded our business model and added additional revenue opportunities. We can now have another type of discussion with both bulk vaccine suppliers and international organizations in vaccination. We have published a so called White-Paper on our homepage which summarizes the advantages and significant cost savings possible with our technology. It also means that we work to ensure that our technology can deliver an end product that is adapted to the wishes and requirements of both industry and, not least, end users. Our ambition is to be one step ahead and able to offer a unique complete solution for how a dry-formulated vaccine can be produced, handled and administered. The capital we raised during the summer will largely be used for this business area, thus accelerating the commercialization of our technology. Our external network of contacts is constantly expanding, and we are receiving increasing recognition from a number of players in the industry. Our White Paper has been much appreciated by a significant key player. We have previously announced three industrial collaboration agreements with the aim of evaluating our technology in their respective projects. The ongoing pandemic has caused delays, partly due to shutdowns in the countries where our partners operate. Thus, our goal to enter into collaboration in at least one license agreement during the year may be delayed intil 2021. At the same time, the Covid-19 pandemic clearly indicates the need to solve the cold chain problem. We also continue to develop our commercial work by collaborating with various companies and groups that work for a better uptake of vaccinations worldwide, in order to increase knowledge about the importance of our method. We are developing stronger and ever more valuable relationships in these organizations and we have high hopes of being able to formalize a collaboration with one of these actors in the coming year. In summary, we are well on our way to delivering on our goals for the current year and to position Ziccum for a very exciting future in an industry that will have a very large focus for a long time to come. Finally, I would like to welcome all our new shareholders who joined us during the quarter and to thank all of our shareholders for their confidence. Lund, November 6, 2020 Göran Conradson, CEO. READ THE WHOLE REPORT HERE ( http://ziccum.com/investors/financial-reports/ ) |
||||
2020-11-04 | Ziccum | Ziccum AB: BioStock: Ziccum - Nu är det dags för handling | Pressreleaser | Visa Stäng |
|
||||
2020-11-02 | Ziccum | Ziccum AB: ZICCUM AB releases blueprint of world's first industrial plant producing air-dried vaccines requiring no Cold Chain | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-10-26 | Ziccum | Ziccum AB: ZICCUM AB har utsett Frida Hjelmgren till ny CFO fr.o.m 1 januari 2021 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-10-19 | Ziccum | Ziccum AB: ZICCUM publicerar White Paper som beskriver världens första anläggning för storskalig produktion av temperaturstabila vacciner | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-10-19 | Ziccum | Ziccum AB: ZICCUM to publish White Paper on world's first industrial air-drying of vaccines using its LaminarPace technology | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-10-16 | Ziccum | Ziccum AB: BioStock: Ziccum kommenterar det framgångsrika vaccinprojektet | Pressreleaser | Visa Stäng |
|
||||
2020-10-15 | Ziccum | Ziccum AB: ZICCUM takes lead on new pilot study of vaccine plant producing cost-effective thermostable vaccines at volume with KeyPlants as engineering partner | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-10-15 | Ziccum | Ziccum AB: ZICCUM har genomfört en pilotstudie på storskalig produktion av temperaturstabila vacciner i partnerskap med KeyPlants | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-09-29 | Ziccum | Ziccum AB: BioStock: Ziccum eliminerar vacciners akilleshäl | Pressreleaser | Visa Stäng |
|
||||
2020-09-18 | Ziccum | Ziccum AB: BioStock: Ziccum kan bli nyckelspelare inom vaccintillverkning | Pressreleaser | Visa Stäng |
|
||||
2020-09-15 | Ziccum | Ziccum AB: ZICCUM AB: global vaccine cold chain moves to top of news agenda as world calls for action | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-09-15 | Ziccum | Ziccum AB: ZICCUM AB: global vaccine cold chain moves to top of news agenda as world calls for action | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-09-04 | Ziccum | Ziccum AB: ZICCUM AB submits patent applications for improved operation of the LaminarPace system for commercial vaccine production | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-09-04 | Ziccum | Ziccum AB: ZICCUM AB lämnar in patentansökningar avseende förbättrad funktion av LaminarPace systemet för kommersiell vaccinproduktion | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-08-21 | Ziccum | Ziccum AB: Penser Access: Ziccum - En teknologi på en marknad med hela världens fokus | Pressreleaser | Visa Stäng |
|
||||
2020-08-20 | Ziccum | Ziccum AB: ZICCUM AB Delårsrapport 1 januari-30 juni 2020 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2020-08-20 | Ziccum | Ziccum AB: ZICCUM AB interim report January 1-June 30, 2020 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2020-07-10 | Ziccum | Ziccum AB: ZICCUM AB submits patent application for thermostable dry-powder formulations of VLP-based vaccines (Virus-Like Particles) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-07-10 | Ziccum | Ziccum AB: ZICCUM AB lämnar in patentansökan avseende termostabila formuleringar av VLP baserade vacciner (Virus Like Particles). | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-06-24 | Ziccum | Ziccum AB (publ) genomför riktad nyemission om 38,8 MSEK för att accelerera utvecklingen av temperaturstabila vacciner | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-06-24 | Ziccum | Ziccum AB (publ) completes directed share issue of SEK 38.8 million to accelerate development of temperature-stable vaccines | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-06-23 | Ziccum | Ziccum AB (publ) utreder förutsättningarna för att genomföra en riktad nyemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-06-16 | Ziccum | Ziccum AB: Ziccum: Beslut vid årsstämman den 16 juni 2020 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-06-05 | Ziccum | Ziccum AB (publ): Beslutsförslag till årsstämman avseende styrelsen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-05-20 | Ziccum | Ziccum AB (publik) tar nästa steg i ett av sina industriella utvecklingssamarbeten | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-05-14 | Ziccum | Ziccum AB (publ): KALLELSE TILL ÅRSSTÄMMA i ZICCUM AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-04-30 | Ziccum | Ziccum AB tar upp Företagslån om 2 MSEK från ALMI | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-04-23 | Ziccum | Ziccum AB: ZICCUM AB (publ) Flagging message (regulatory) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-04-23 | Ziccum | Ziccum AB (publ) Flaggningsmeddelande (Regulatorisk) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-04-20 | Ziccum | Ziccum AB: Penser Access: Ziccum - Stort steg framåt med nytt samarbete | Pressreleaser | Visa Stäng |
|
||||
2020-04-17 | Ziccum | Ziccum AB: ZICCUM AB First Quarter Report, Q1 2020 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-04-17 | Ziccum | Ziccum AB: ZICCUM AB Delårsrapport Q1 2020 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-04-16 | Ziccum | Ziccum AB publicerar årsredovisning för 2019 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-04-08 | Ziccum | Ziccum AB (publ): Corfind intervjuar VD Göran Conradson om pågående verksamhet och vägen framåt för bolaget i Coronatider | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-03-26 | Ziccum | Ziccum AB: ZICCUM signs Letter of Intent to explore integrating Ziccum technology into innovative vaccine biomanufacturing line | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-03-26 | Ziccum | Ziccum AB: ZICCUM tecknar avsiktsförklaring att undersöka integration av Ziccums teknologi in i en innovativ vaccintillverkningsprocess | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-02-14 | Ziccum | Ziccum AB: Penser Access: Ziccum - Nyheter kring samarbeten att vänta 2020 | Pressreleaser | Visa Stäng |
|
||||
2020-02-13 | Ziccum | Ziccum AB (publ): Bokslutskommuniké 1 januari - 31 december 2019 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2020-02-13 | Ziccum | Ziccum AB (publ) Year-end report January 1 - December 31, 2019 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2020-02-07 | Ziccum | Ziccum AB: ZICCUM AB (publ) Flaggningsmeddelande (Regulatorisk) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2020-01-07 | Ziccum | Ziccum AB: Utfall av nyttjande av teckningsoptioner i Ziccum: Nyttjandegraden uppgick till 92,6 procent | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-12-20 | Ziccum | Ziccum AB: ZICCUM AB submits patent application for new temperature-stable, dry-powder formulation of virus belonging to same family as Measles | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-12-19 | Ziccum | Ziccum AB: ZICCUM AB engages Emerging Viral Diseases unit of Aix-Marseille University to develop dry viruses and vaccines, strengthening Ziccum's future IP portfolio | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-12-19 | Ziccum | Ziccum AB: Ziccums styrelse och VD tecknar aktier med stöd av teckningsoptioner | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-12-10 | Ziccum | Ziccum AB (publ): Corfind intervjuar VD Göran Conradson om pågående lösen av teckningsoptioner, målsättningar för 2020 och vägen framåt för bolaget | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-11-11 | Ziccum | Ziccum AB: Penser Access: Ziccum - Eliminera kylkedjan för vaccin | Pressreleaser | Visa Stäng |
|
||||
2019-10-21 | Ziccum | Ziccum AB: Penser Access: Ziccum - Dags att eliminera kylkedjan för vaccin | Pressreleaser | Visa Stäng |
|
||||
2019-10-21 | Ziccum | Ziccum AB: Erik Penser Bank publicerar analys av Ziccum | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-10-03 | Ziccum | Ziccum AB: Ziccum ingår ett avtal för utvärdering med ett globalt läkemedels- och vaccinbolag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-10-03 | Ziccum | Ziccum AB: Ziccum enters into evaluation agreement with global pharmaceutical and vaccine company | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-08-21 | Ziccum | Ziccum AB: ZICCUM AB Half Year Report Q2 2019 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-08-21 | Ziccum | Ziccum AB: ZICCUM AB Delårsrapport Q2 2019 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-07-02 | Ziccum | Ziccum AB (publ) ska genomföra förstudie åt vaccinutvecklingsbolag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-07-02 | Ziccum | Ziccum AB (publ) to carry out Proof-of-Concept feasibility study for pharma formulation company | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-06-28 | Ziccum | Ziccum AB: Ziccum erhåller forskningsanslag från Vinnovaccum AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-06-28 | Ziccum | Ziccum AB: Ziccum receives research grant from Vinnova AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-05-29 | Ziccum | Ziccum AB (publ) Flagging message (regulatory) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-05-29 | Ziccum | Ziccum AB (publ) Flaggningsmeddelande (Regulatorisk) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-05-20 | Ziccum | Report from Ziccum AB (publ) Annual General Meeting, May 20, 2019 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-05-20 | Ziccum | Kommuniké från Ziccum AB (publ) årsstämma den 20 maj 2019 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-05-09 | Ziccum | Ziccum AB: senior Astra Zeneca vaccine & biopharmaceutical strategist to be new Board member | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-05-09 | Ziccum | Ziccum AB: Ziccum Q1 Report 2019 released | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-05-09 | Ziccum | Ziccum AB publicerar Delårsrapport Q1 2019 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-04-16 | Ziccum | Ziccum AB: KALLELSE TILL ÅRSSTÄMMA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-04-16 | Ziccum | Ziccum AB: NOTICE OF ANNUAL GENERAL MEETING | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-04-15 | Ziccum | Ziccum AB: Ziccum Annual Report for 2018 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-04-15 | Ziccum | Ziccum AB: Ziccum publicerar årsredovisning för 2018 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2019-02-21 | Ziccum | Ziccum AB: ZICCUM AB (publ) Bokslutskommuniké 2018 (Correction) | Rapporter | Ladda ner | Visa Stäng |
|
||||
2019-02-21 | Ziccum | Ziccum AB: ZICCUM AB (publ) Q4 and Year-End Report 2018 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2019-02-21 | Ziccum | Ziccum AB: ZICCUM AB (publ) Bokslutskommuniké 2018 | Rapporter | Ladda ner | Visa Stäng |
|